Merus NV (STU:2GH) Accounts Payable : €6.89 Mil (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Merus NV Accounts Payable?

Merus NV's Accounts Payable for the quarter that ended in Mar. 2024 was €6.89 Mil.

Merus NV's quarterly Accounts Payable increased from Sep. 2023 (€3.60 Mil) to Dec. 2023 (€4.22 Mil) and increased from Dec. 2023 (€4.22 Mil) to Mar. 2024 (€6.89 Mil).

Merus NV's annual Accounts Payable declined from Dec. 2021 (€11.72 Mil) to Dec. 2022 (€9.28 Mil) and declined from Dec. 2022 (€9.28 Mil) to Dec. 2023 (€4.22 Mil).

Merus NV Accounts Payable Historical Data

The historical data trend for Merus NV's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Merus NV Accounts Payable Chart

Merus NV Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Payable

Get a 7-Day Free Trial

2.73

2.57

11.72

9.28

4.22

Merus NV Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Accounts Payable	Get a 7-Day Free Trial															4.66	7.01	3.60	4.22	6.89

Merus NV Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Merus NV Accounts Payable Related Terms

Thank you for viewing the detailed overview of Merus NV's Accounts Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Merus NV (STU:2GH) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Merus NV (STU:2GH) » Definitions » Accounts Payable

Comparable Companies

Traded in Other Exchanges

MRUS:USA 2GH:Germany

Address

Uppsalalaan 17, Utrecht, NLD, 3584 CT

Website

https://www.merus.nl

Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics. Merus only reportable segment comprising the discovery and development of innovative bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.

Merus NV (STU:2GH) Headlines

No Headlines